Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update Feb 23, 2023 8:00am EST
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000 Jan 24, 2023 8:00am EST
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery Dec 08, 2022 8:00am EST
Baudax Bio Reports Third Quarter 2022 Financial Results and Business Highlights Nov 08, 2022 4:09pm EST
Baudax Bio Announces Distribution of Series B Preferred Stock to Holders of its Common Stock Sep 19, 2022 4:05pm EDT
Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference Sep 08, 2022 4:05pm EDT